CLINICAL EFFICACY OF PREBIOTICS AND GLYCOSAMINOGLYCANS VERSUS PLACEBO IN DOGS WITH FOOD RESPONSIVE ENTEROPATHY RECEIVING A HYDROLYZED DIET: A PILOT STUDY

Comunicación Libre

Gastroenterología

(1) Departments of Veterinary Clinical Sciences, Royal Veterinary College (RVC), University of London, UK
(2) Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA
(3) Veterinary Pathology and Pathobiology, RVC,University of London, UK
(4) Clinical Sciences and Advanced Medicine, University of Pennsylvania College of Veterinary Medicine, Philadelphia, PA, USA
(5) Department of Veterinary Clinical Sciences, Iowa State University, Ames, IA, USA
(6) R&D Bioiberica S.A.U., Barcelona, Spain

Barbara Glanemann (1)
Yeon-jung Seo (2)
Simon L. Priestnall (3)
Oliver A. Garden (4)
Albert E. Jergens (5)
Sergi Segarra (6)
Jonathan P. Mochel (2)
Karin Allenspach (5)

RESUMEN CORTO - SHORT SUMMARY

Induction of remission is easily achieved with dietary treatment in dogs with Food Responsive Chronic Enteropathy (FRD). Administration of prebiotics and glycosaminoglycans (GAGs) may be useful as adjunct treatment. This randomized, controlled clinical trial evaluated whether the clinical evolution of FRD dogs that are switched back to their normal diet can be influenced using supplemental treatment with prebiotics and GAGs.

Dogs were diagnosed based on clinical exclusion diagnosis, endoscopic biopsies and response to dietary treatment and randomized to receive prebiotics plus GAGs (group 1) or placebo (group 2) in addition to hydrolyzed diet. After 10 weeks, dogs were switched back to normal diet and clinical evolution was monitored until week 18.

Dietary treatment led to significant clinical improvements in both groups. Of the 35 dogs enrolled into the clinical trial, 20 reached week 10 and 13 reached the trial endpoint of 18 weeks. After switching back to normal diet, none of the dogs in either group relapsed and no significant differences were found over time or between groups for CCECAI, clinicopathological data, and endoscopy and histological scoring. Although after switching back to the original diet there was a clinical worsening in the placebo group that did not occur in the supplement group, this was not statistically significant.

In conclusion, because the study was underpowered, it was not possible to determine whether supplementation with prebiotics and GAGs had an additional effect to dietary treatment. Since there are very few RCCT published in chronic enteropathies CE in dogs, this pilot study provides important power analyses for planning of further studies.

BIBLIOGRAFÍA

1.        Allenspach K. Clinical Immunology and Immunopathology of the Canine and Feline Intestine. Vet Clin North Am - Small Anim Pract. 2011;41(2):345-360.

2.        Allenspach K, Culverwell C, Chan D. Long-term outcome in dogs with chronic enteropathies: 203 cases. Vet Rec. 2016;178(15):368.2-368.

3.        Segarra S, Martínez-Subiela S, Cerdà-Cuéllar M, et al. Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial. BMC Vet Res. 2016;12(1):49.

4.        Allenspach K, Wieland B, Gröne A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21(4):700-708.

5.        Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med. 2003;17(3):291-297.